12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ganetespib: Phase II started

Synta disclosed in its 3Q12 earnings that it began the open-label Phase II ENCHANT trial to evaluate twice-weekly 150 mg/m 2 IV ganetespib for 3 consecutive weeks in a 4-week cycle in about 70...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >